Orexo gains US rights to vorvida, a digital therapy for alcohol use disorder

27 November 2019

Swedish drug developer Orexo (STO: ORX) today announced it has acquired the exclusive US rights to vorvida, a digital therapy for the treatment of alcohol use disorder (AUD), from GAIA AG, a global leader in digital therapeutics.

Today’s news follows an earlier agreement with GAIA in August 2019, for the exclusive global commercial rights to OXD01, a new digital therapy being developed for the treatment of opioid use disorder (OUD).

Under the terms of the new agreement, Orexo will be responsible for the regulatory approval and commercialization of vorvida in the USA, while GAIA will be entitled to an undisclosed upfront payment, milestone payments as well as royalties. Orexo and GAIA will initiate a dialog with the Food and Drug Administration about the regulatory pathway, the outcome of which will decide the launch timing and requirement for additional investments in the development of vorvida for the US market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK